Core Insights - GENFIT presents promising preclinical data for investigational drug G1090N, aimed at treating Acute-on-Chronic Liver Failure (ACLF) with nitazoxanide (NTZ) [1][4] - The drug is designed to optimize dose-response and provide dosing flexibility for patients with varying degrees of renal or hepatic impairment [1][4] - Preclinical findings indicate NTZ's efficacy in reducing systemic inflammation and improving organ function in ACLF disease models [3][6] Company Overview - GENFIT is a biopharmaceutical company focused on rare and life-threatening liver diseases, with over two decades of research and development experience [5] - The company has a diversified R&D portfolio targeting conditions associated with ACLF, including Acute Decompensation and Hepatic Encephalopathy [5] - GENFIT has successfully developed and commercially launched Iqirvo® (elafibranor) for Primary Biliary Cholangitis, demonstrating its capability in advancing high-potential molecules [5] Research and Development - A Phase 1 First-in-Human study for G1090N is currently underway, with safety data expected by the end of 2025 [4][6] - Initial efficacy signals from ex-vivo functional assays are also anticipated at the same time [4][6] - The company aims to initiate a Phase 2 proof-of-concept study in the first half of 2026, contingent on positive results from ongoing studies [7]